上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2021 , Vol. 41 >Issue 8: 1046 - 1050

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.08.008

论著 · 临床研究

简化整体抗磷脂抗体综合征评分在系统性红斑狼疮患者新发血栓栓塞事件风险评估中的应用研究

  • 李佳 ,
  • 王然 ,
  • 鲍春德 ,
  • 沈南 ,
  • 扶琼
展开
  • 上海交通大学医学院附属仁济医院风湿科，上海 200001
李佳（1980—），女，回族，副主任医师，博士；电子信箱：leejiasjtu@163.com。
扶琼，电子信箱：fuqiong5@163.com。

网络出版日期: 2021-08-13

基金资助

国家自然科学基金(81102267);上海青年医师培养资助计划

收起

Application of adjusted global antiphospholipid syndrome score to risk assessment of new thromboembolic events in patients with systemic lupus erythematosus

  • Jia LI ,
  • Ran WANG ,
  • Chun-de BAO ,
  • Nan SHEN ,
  • Qiong FU
Expand
  • Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China
FU Qiong, E-mail: fuqiong5@163.com.

Online published: 2021-08-13

Supported by

National Natural Science Foundation of China(81102267);Youth Medical Talent-Specialist Program

Fold

摘要

目的·验证简化整体抗磷脂抗体综合征评分（adjusted global antiphospholipid syndrome score，aGAPSS）在系统性红斑狼疮（systemic lupus erythematosus，SLE）患者新发血栓栓塞事件风险评估中的效能。方法·回顾性分析2012年12月—2016年3月于上海交通大学医学院附属仁济医院住院的SLE患者330例。根据患者住院期间是否存在新发血栓栓塞事件，将其分为血栓组和对照组。收集2组患者的人口统计学数据、临床资料，并根据5项风险指标计算aGAPSS。通过受试者操作特征曲线（receiver operator characteristic curve，ROC curve，ROC曲线）评价aGAPSS在患者新发血栓栓塞事件中的诊断效能。结果·共计有60例（18.2%）患者存在新发血栓栓塞事件。与对照组相比，血栓组患者aGAPSS显著升高（P=0.000）。ROC曲线结果显示，当aGAPSS大于7分时，对SLE患者新发血栓栓塞事件诊断的曲线下面积为0.752（95%CI 0.702~0.797），其灵敏度和特异度分别为48.33%和94.07%。结论·aGAPSS可用于评估SLE患者血栓栓塞事件的发生风险，并可为临床治疗决策提供参考。

关键词： 系统性红斑狼疮; 血栓栓塞; 简化整体抗磷脂抗体综合征评分

本文引用格式

李佳 , 王然 , 鲍春德 , 沈南 , 扶琼 . 简化整体抗磷脂抗体综合征评分在系统性红斑狼疮患者新发血栓栓塞事件风险评估中的应用研究[J]. 上海交通大学学报（医学版）, 2021 , 41(8) : 1046 -1050 . DOI: 10.3969/j.issn.1674-8115.2021.08.008

Abstract

Objective

·To verify the efficacy of adjusted global antiphospholipid syndrome score (aGAPSS) in the risk assessment of new thromboembolic events in the patients with systemic lupus erythematosus (SLE).

Methods

·A total of 330 SLE patients admitted to Renji Hospital, Shanghai Jiao Tong University School of Medicine from December 2012 to March 2016 were retrospectively analyzed. The patients were divided into thrombosis group and control group according to whether there were new thromboembolic events during hospitalization. Demographic data and clinical data of the two groups were collected, and aGAPSS was calculated according to the five risk indicators. Receiver operator characteristic curve (ROC curve) was used to evaluate the diagnostic efficacy of aGAPSS in the patients with new thromboembolic events.

Results

·A total of 60 patients (18.2%) had new thromboembolic events. Compared with the control group, aGAPSS significantly increased in the thrombosis group (P=0.000). The results of ROC curve showed that when the aGAPSS>7 scores, the area under the curve for the diagnosis of new thromboembolic events was 0.752 (95%CI 0.702-0.797), and the sensitivity and specificity were 48.33% and 94.07%, respectively.

Conclusion

·aGAPSS can be used to assess the risk of thromboembolic events in SLE patients and provide reference for clinical treatment decision-making.

Key words： systemic lupus erythematosus (SLE); thromboembolism; adjusted global antiphospholipid syndrome score (aGAPSS)

参考文献

1 Arkema EV, Svenungsson E, von Euler M, et al. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study[J]. Ann Rheum Dis, 2017, 76(9): 1544-1549.
2 Avi?a-Zubieta JA, Vostretsova K, De Vera MA, et al. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: a general population-based study[J]. Semin Arthritis Rheum, 2015, 45(2): 195-201.
3 Guraieb-Chahín P, Cantú-Brito C, Soto-Mota A, et al. Stroke in systemic lupus erythematosus: epidemiology, mechanism, and long-term outcome[J]. Lupus, 2020, 29(5): 437-445.
4 Sciascia S, Sanna G, Murru V, et al. GAPSS: the global anti-phospholipid syndrome score[J]. Rheumatology (Oxford), 2013, 52(8): 1397-1403.
5 Sciascia S, Radin M, Sanna G, et al. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis[J]. Rheumatology (Oxford), 2018, 57(4): 661-665.
6 Radin M, Sciascia S, Erkan D, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort[J]. Semin Arthritis Rheum, 2019, 49(3): 464-468.
7 Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(8): 2677-2686.
8 D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study[J]. Circulation, 2008, 117(6): 743-753.
9 Garcia L, Velloso MS, Martire MV, et al. Validation of the adjusted global antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina[J]. Lupus, 2020, 29(14): 1866-1872.
10 Radin M, Schreiber K, Costanzo P, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction[J]. Int J Cardiol, 2017, 240: 72-77.
11 Bahl V, Hu HM, Henke PK, et al. A validation study of a retrospective venous thromboembolism risk scoring method[J]. Ann Surg, 2010, 251(2): 344-350.
12 Hernández-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome[J]. Clin Exp Rheumatol, 2013, 31(3): 382-388.
13 Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events[J]. Arthritis Rheum, 2012, 64(2): 504-512.
14 Chen J, Sun S, Yan Q, et al. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study[J]. Clin Rheumatol, 2016, 35(2): 333-340.
15 Zuily S, de Laat B, Mohamed S, et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study[J]. Rheumatology (Oxford), 2015, 54(11): 2071-2075.
16 Sciascia S, Cuadrado MJ, Sanna G, et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort[J]. Arthritis Care Res (Hoboken), 2014, 66(12): 1915-1920.
Options
文章导航

/

〈 〉